Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey Pharmaceutical Materials, Inc., 19017 [2013-07140]

Download as PDF Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices 19017 DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE DEPARTMENT OF LABOR Drug Enforcement Administration Drug Enforcement Administration Office of the Secretary Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey Pharmaceutical Materials, Inc. Manufacturer of Controlled Substances; Notice of Registration; Siemens Healthcare Diagnostics, Inc. Agency Information Collection Activities; Submission for OMB Review; Comment Request; Annual Funding Notice for Defined Benefit Pension Plans Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 15, 2012, Johnson Matthey Pharmaceutical Materials, Inc., Pharmaceutical Service, 25 Patton Road, Devens, Massachusetts 01434, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: By Notice dated November 27, 2012, and published in the Federal Register on December 5, 2012, 77 FR 72409, Siemens Healthcare Diagnostics Inc., Attn: RA, 100 GBC Drive, Mail Stop 514, Newark, Delaware 19702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Drug Schedule Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Nabilone (7379) ............................ Hydrocodone (9193) ..................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Tetrahydrocannabinols (7370) ..... Ecgonine (9180) ........................... Morphine (9300) ........................... II II II II II II II I II II mstockstill on DSK4VPTVN1PROD with NOTICES The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 28, 2013. The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator controls which are DEA exempt products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siemens Healthcare Diagnostics Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Siemens Healthcare Diagnostics Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: March 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–07140 Filed 3–27–13; 8:45 am] [FR Doc. 2013–07141 Filed 3–27–13; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P VerDate Mar<15>2010 20:20 Mar 27, 2013 Jkt 229001 PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 ACTION: Notice. SUMMARY: The Department of Labor (DOL) has submitted the Employee Benefits Security Administration (EBSA) sponsored information collection request (ICR) revision titled, ‘‘Annual Funding Notice for Defined Benefit Pension Plans,’’ to the Office of Management and Budget (OMB) for review and approval utilizing emergency review procedures, in accordance with the Paperwork Reduction Act of 1995, Public Law 104– 13, 44 U.S.C. chapter 35 (PRA) and 5 CFR 1320.13. DATES: OMB approval of the revised ICR has been requested by April 29, 2013. Submit comments on or before April 26, 2013. ADDRESSES: A copy of this ICR, with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained from the RegInfo.gov Web site, http://www.reginfo.gov/ public/do/PRAMain, or by contacting G. Christopher Cosby at, Department of Labor-EBSA, Room N–5718, 200 Constitution Avenue NW., Washington, DC 20210, telephone, (202) 693–8410; FAX, (202) 219–4745 (these are not tollfree numbers); email, cosby.chris@dol.gov. Submit comments about this request to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for the Department of LaborEBSA, Office of Management and Budget, Room 10235, 725 17th Street NW., Washington, DC 20503, Fax: 202– 395–6881 (these are not toll-free numbers), email: OIRA_submission@omb.eop.gov; and G. Christopher Cosby Department of LaborEBSA, Room N–5718, 200 Constitution Avenue NW., Washington, DC 20210, telephone, (202) 693–8410; FAX, (202) 219–4745 (these are not toll-free numbers); email, cosby.chris@dol.gov. SUPPLEMENTARY INFORMATION: On July 6, 2012, President Barrack Obama signed the Moving Ahead for Progress in the 21st Century Act (MAP–21). The new law provides funding interest-rate stabilization for single employer defined benefit (DB) plans, effective for plan years beginning on and after January 1, E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Page 19017]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07140]



[[Page 19017]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Johnson Matthey Pharmaceutical Materials, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 15, 2012, Johnson 
Matthey Pharmaceutical Materials, Inc., Pharmaceutical Service, 25 
Patton Road, Devens, Massachusetts 01434, made application by renewal 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Hydrocodone (9193).........................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
------------------------------------------------------------------------

    The company plans to utilize this facility to manufacture small 
quantities of the listed controlled substances in bulk and to conduct 
analytical testing in support of the company's primary manufacturing 
facility in West Deptford, New Jersey. The controlled substances 
manufactured in bulk at this facility will be distributed to the 
company's customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 28, 2013.

    Dated: March 20, 2013.
Joseph T. Rannazzisi,
 Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-07140 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P